VITRAKVI 20 mg/ml, oral solution 2 bottles of 50 ml
Active ingredients: Larotrectinib, Larotrectinib sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Oral solution2 bottles of 50 mlorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VITRAKVI 20 mg/mL, solution buvable
- Pharmaceutical form
- solution buvable
- Route of administration
- orale
- Presentation description
- 2 flacon(s) en verre avec fermeture de sécurité enfant de 50 ml
- Marketing authorisation holder
- BAYER AG (ALLEMAGNE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 13 Jul 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65942815CIP73023034CIP133400930230343Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAROTRECTINIBsolution | 20 mg · 1 mL de solution buvable | FT |
| SULFATE DE LAROTRECTINIBsolution | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.